Molecular Profiling of GBM Patients Developed Pseudoprogression After Chemoradiation Treatment | Caris Life Sciences
Home / Research / Publications / Molecular Profiling of GBM Patients Developed Pseudoprogression After Chemoradiation Treatment

Publications

Molecular Profiling of GBM Patients Developed Pseudoprogression After Chemoradiation Treatment

Introduction

Pseudoprogression (psPD) is now recognized following radiotherapy with concurrent temozolomide (RT/TMZ) for glioblastoma multiforme (GBM). The purpose of this study was to explore biomarker expression profile of GBM patients with psPD.

Download Publication
Learn More
Name(Required)